We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-21.84%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$218M
AUM Growth
-$87.2M
Cap. Flow
-$10.3M
Cap. Flow %
-4.72%
Top 10 Hldgs %
82.07%
Holding
26
New
5
Increased
5
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$12.3M
2
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$9.96M
3
CBAY
Cymabay Therapeutics
CBAY
+$5.79M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$5.14M
5
SIBN icon
SI-BONE Inc
SIBN
+$3.89M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$16.7M
2
OMER icon
Omeros
OMER
+$8.69M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$8.21M
4
ABUS icon
Arbutus Biopharma
ABUS
+$5.39M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 85.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
26
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-1,000,919
Closed -$16.7M
1
2

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q4 2018 Portfolio in Review

As of Q4 2018, Foresite Capital Management IV held 26 positions worth $218M, down 29% from $305M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Foresite Capital Management IV withdrew a net $10.3M in Q4 2018, closing 8 positions and reducing 6 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $16.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 92% a quarter earlier.

Against the trend, Foresite Capital Management IV opened a new position in Aerie Pharmaceuticals worth $9.45M.

  • Foresite Capital Management IV's largest Q4 2018 buy was Aerie Pharmaceuticals: 261,823 shares worth $9.45M.
  • Foresite Capital Management IV added most to Cymabay Therapeutics in Q4 2018, an estimated $5.79M increase.
  • Foresite Capital Management IV's biggest Q4 2018 reduction was Rhythm Pharmaceuticals, cutting an estimated $8.21M.
  • Foresite Capital Management IV fully exited Alder Biopharmaceuticals in Q4 2018, selling an estimated $16.7M.
  • Foresite Capital Management IV's ten largest holdings make up 82% of its $218M portfolio in Q4 2018.
  • Foresite Capital Management IV opened 5 new positions and closed 8 in Q4 2018.
  • Foresite Capital Management IV's portfolio value fell 29% quarter-over-quarter to $218M.

Based on Foresite Capital Management IV's 13F filing for Q4 2018, filed 13 Feb 2019.